Considering the poor outcomes of AITL with standard CHOP-based therapy—particularly among high-risk patients—alternative chemotherapy backbones or the incorporation of novel agents such as brentuximab vedotin, histone deacetylase inhibitors, or JAK/STAT pathway inhibitors into frontline treatment may offer clinical benefit (22–24). Here, SOAT1 is linked to angioimmunoblastic T-cell lymphoma.